The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions
Jürgen Behr(Ludwig-Maximilians-Universität München), Athol U. Wells(St Thomas' Hospital), Tamera J. Corte(The University of Sydney), Vincent Cottin(Université Claude Bernard Lyon 1), Simon Walsh(Royal Brompton & Harefield NHS Foundation Trust), Gary M. Hunninghake(Hubei University of Science and Technology), Luca Richeldi(Coral Reef Alliance), Mary Beth Beasley(Icahn School of Medicine at Mount Sinai), Ganesh Raghu(University of Washington), Lida P. Hariri(Harvard University), Christopher J. Ryerson(University of British Columbia), Anna J. Podolanczuk(Cornell University), Allan R. Glanville(Macquarie University), Margaret L. Salisbury(Unknown), Ayodeji Adegunsoye(University of Chicago), Wim Wuyts(Universitair Ziekenhuis Leuven), Cory M. Hogaboam(Cedars-Sinai Medical Center), Imre Noth(University of Virginia), Martin Kolb(McMaster University), Justin M. Oldham(Michigan Medicine)
Cited by 38
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k